WAKAMOTO PHARMACEUTICAL CO.,LTD. (4512.T) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 20Aug 25Aug 28Sep 2Sep 7Sep 10Sep 15Sep 18

Key dataSep 18, 2026

OpenJPY 299.00

From 52W high−17.86%

Volume17600.00

Market capJPY 10.38B

P/E (TTM)30.3x

P/S (TTM)1.0x

Div yield1.00%

Key dataSep 18, 2026

Open

JPY 299.00

From 52W high

−17.86%

Volume

17600.00

Market cap

JPY 10.38B

ValuationView details →

P/E (Fwd)

60.2x

EV/EBITDA

12.6x

P/E (TTM)

30.3x

RSI (14)

53.8

MomentumView details →

1D Return

−0.33%

YTD Return

+4.20%

ValuationView details →

P/E (Fwd)

60.2x

P/E (TTM)

30.3x

EV/EBITDA

12.6x

EV/Sales

0.9x

P/S (TTM)

1.0x

P/B (TTM)

0.9x

ProfitabilityView details →

Gross Margin

38.98%

Net Margin

3.21%

EBITDA Margin

−0.29%

ROE (TTM)

2.46%

ROA (TTM)

1.88%

Asset Turnover

0.61x

GrowthView details →

Revenue YoY

+16.78%

EPS YoY

+1.36%

FCF YoY

—

Revenue CAGR 3Y

−2.42%

EPS CAGR 3Y

−35.42%

EBITDA YoY

—

MomentumView details →

1D Return

−0.33%

YTD Return

+4.20%

1Y Return

−0.33%

RSI (14)

53.8

vs 50D SMA

+4.50%

vs 200D SMA

−1.38%

Capital & dividendView details →

Debt/Equity

0.01x

Current Ratio

4.00x

Quick Ratio

3.03x

Div Yield

1.00%

Div Rate

—

Div Growth 1Y

+0.00%

EarningsView details →

EPS (Actual)

—

EPS Surprise

—

Beats (12Q)

—

Next Q EPS Est

—

Avg Surprise (4Q)

—

Rev Surprise

—

Financials snapshotView financials →

Revenue (TTM)

9.29B

Net Income (TTM)

298.00M

Op. CF (TTM)

—

Next earningsNov 9, 2026 →

Latest newsMore news →

Asset Value Investors, a London-based investment adviser, increased its shareholding in Wakamoto Pharmaceutical from 10.60% to 11.64%, as disclosed in a change report filed with the Kanto Finance Bureau on August 27, 2026.24d ago

Similar companies

StemRIM Inc.4599.T Immuno-Biological Laboratories Co.,Ltd.4570.T KAINOS Laboratories,Inc.4556.T K Pharma,Inc.4896.T MORISHITA JINTAN CO.,LTD.4524.T AnGes,Inc.4563.T Find similar companies →

Latest newsMore news →

Asset Value Investors, a London-based investment adviser, increased its shareholding in Wakamoto Pharmaceutical from 10.60% to 11.64%, as disclosed in a change report filed with the Kanto Finance Bureau on August 27, 2026.24d ago